Article
Progesterone receptor membrane component 2 expression leads to erlotinib resistance in lung adenocarcinoma cells.
Die Pharmazie - 5 Dec 2021
Hanamuro S, Lin Y, Konishi H, Izusawa K, Yang L, Haga Y, Tsujino H, Nagano K, Higashisaka K, Tsutsumi Y
Abstract excerpt
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) provide a favorable treatment outcome in patients with EGFR mutation-positive non-small cell lung cancer. However, most of such patients become resistant to EGFR-TKIs within a year. Thus, clarifying the mechanism of acquired resistance to EGFR-TKIs has been a research focus. Here, we demonstrated that the expression of progesterone receptor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.